Latest Earnings Results: Q2 '26
Estimated EPS
$0.06
Reported EPS
$0.09
Surprise
+59.94%
Estimated Rev
$355.96M
Reported Rev
$387.5M
Surprise
+8.86%
• Reported GAAP EPS of $0.18 up 126.47% YoY • Reported revenue of $387.5M up 51.93% YoY
Bullish Takeaway
Legend Biotech demonstrated strong commercial momentum with 50% CARVYKTI sales growth, achieved significant clinical proof-of-concept for its LB2501 pipeline candidate, and bolstered its balance sheet through a successful equity offering.
Bearish Takeaway
Legend Biotech experienced revenue declines from Novartis and related party license agreements, while facing ongoing tax negotiation uncertainties that could result in material differences from reported financial statement estimates.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q2 '26 | $0.06 | $0.09 | 59.94% | BEAT |
Q1 '26 | $0.01 | -$0.15 | -1320.60% | MISSED |
Q4 '25 | $0.04 | -$0.08 | -323.83% | MISSED |
Q3 '25 | -$0.07 | -$0.11 | -51.30% | MISSED |
Q2 '25 | -$0.12 | -$0.34 | -195.59% | MISSED |